Hard to Swallow: The Burden of EoE and How We Can Improve Diagnosis and Management
Released On
March 15, 2024
Expires On
September 15, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Gastroenterology, Pediatrics, Primary Care
Topic(s)
Allergies, Pediatrics, Eosinophilic Esophagitis
This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity addresses the needs of gastroenterologists, pediatric gastroenterologists, specialty advanced practice providers, pediatricians and pediatric nurse practitioners, and internal medicine clinicians.
Program Overview
Eosinophilic Esophagitis (EoE) is an immuno-inflammatory disease that affects people of all age groups (including children) and is often triggered by certain foods or aeroallergen microbes. The prevalence of EoE has increased over the past few decades, and few clinicians — including specialists in gastroenterology — are able to recognize the signs and symptoms of this disease. Patients with EoE are often misdiagnosed or go without a correct diagnosis (and appropriate treatment) for several years. What is known to be the appropriate treatment has historically comprised a wide variety of dietary interventions that can be difficult to adhere to and off-label pharmacologics that have mixed efficacy. Since the approval of dupilumab, the first drug ever to be given an EoE indication, treatment options have expanded, offering a new landscape for gastroenterologists, allergists, and other clinicians who manage patients with EoE by giving them a new way to personalize treatment approaches for both their adult and pediatric patients.
Whether you work in primary care, pediatrics, or gastroenterology, follow along with Drs. Chang and Chehade to improve the diagnosis and management of patients with EoE. This self-paced course will allow for a unique learning path based on your current knowledge and skill level and enhance understanding of EoE disease burden and clinical indicators of EoE, improve rates of referral, and assist in the creation of more individualized treatment plans.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Identify signs, symptoms, and clinical indicators of EoE to facilitate referral for specialist evaluation or earlier diagnosis
- Assess the disease burden of EoE and the weight of its effect on physical and psychological quality of life
- Employ strategies for individualized treatment and monitoring of treatment response
- Incorporate new or emerging EoE treatments based on efficacy and safety findings from clinical trials
Faculty
Joy W. Chang, MD MS
Assistant Professor of Internal Medicine
Division of Gastroenterology
University of Michigan
Ann Arbor, Michigan
Mirna Chehade, MD, MPH, AGAF, FAAAAI
Professor of Pediatrics and Medicine
Founding Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York
Physician Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
- Joy W. Chang, MD MS
- Consultant: Sanofi-Regeneron
- Speaker: Sanofi-Regeneron
- Mirna Chehade, MD, MPH, AGAF, FAAAAI
- Consultant: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers SquibbNexstone Immunology, Phathom, Recludix Pharma, Regeneron, Sanofi, Shire/Takeda
- Research Funding: Adare/Ellodi, Allakos, AstraZeneca Regeneron, Bristol Myers Squibb, Danone, Shire/Takeda
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period March 15, 2024 through September 15, 2025, participants must:
- Read the learning objectives
- Complete the pretest
- View the live webcast
- Complete the posttest and the evaluation form at the end of the program
A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, at (855) 835-4004 or [email protected].